Recently, ZHONGZE Therapeutics has completed a Series Pre-A round financing of 10 million dollars. The fund will be used for the development of ZHONGZE's innovative CNS product pipeline, including schizophrenia, substance addiction and neurodegenerative diseases.
ZHONGZE is a clinical stage company focusing on development of innovative drugs for CNS diseases. Through internal R&D and license-in, ZHONGZE has built a unique product pipeline for both domestic and international markets. The core R&D team of ZHONGZE has accumulated more than 100 years of experience in developing novel CNS drugs and has participated in a number of approved and clinical stage CNS drugs around the world. The team has a profound understanding and insight into pathogeneses of CNS diseases, efficient drug development and clinical trials.
Cenova Capital, the current round investor, is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU. It is one of the earliest investors in private healthcare services and digital health which helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. Through the years, Cenova has built a reputation among its current and potential portfolio companies, industry leaders, multinational companies and its peers, as a leading fund for life science investments in China.
The success of this round of financing validatesZHONGZE’s capability in CNS drug R&D. We are confident that ZHONGZE will be able to quickly develop high-quality innovative drugs to meet the urgent unmet need of both CNS patients and their families.